Launching in Summer 2019, The Lancet Rheumatology is a new specialty journal published by The Lancet. This monthly journal is committed to publishing content relevant to rheumatology specialists worldwide, with a focus on studies that advance clinical practice, challenge the status quo, and advocate change in health policy.
Content will include clinical research (with a focus on clinical trials), expert reviews, and provocative comment and opinion relating to the diagnosis & classification, management, and prevention of rheumatic diseases, including arthritic, musculoskeletal, and connective tissue diseases, as well as disorders of the immune system. The journal will also publish high-quality human translational studies that are supported by robust clinical data, with priority given to studies that identify potential new therapeutic targets, advance efforts toward precision medicine, or have the potential to directly inform future clinical trials. With a strong clinical focus, the journal will provide an independent voice for the rheumatology community and will advocate strongly for the improved lives of patients with rheumatic diseases around the globe.
All original research will be subjected to The Lancet's usual rigorous standards of external clinical and statistical peer review, and edited by experienced technical editors to the highest standards. In keeping with other journals in the Lancet family, The Lancet Digital Health offers rapid publication online within 4–8 weeks from submission. For full details of how to submit your paper, please visit https://ees.elsevier.com/tlrheu. We also welcome presubmission enquiries-please contact email@example.com.Visit http://www.thelancet.com/rheumatology for more information.